Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.

Bibliographic Details
Main Authors:	Shipman, C, Holen, I, Lippitt, J, Edwards, T, Croucher, P
Format:	Journal article
Published:	2000

Similar Items

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
by: Shipman, C, et al.
Published: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
by: Shipman, C, et al.
Published: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
by: Croucher, P, et al.
Published: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
by: Croucher, P, et al.
Published: (2000)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
by: Shipman, C, et al.
Published: (2003)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
by: Vanderkerken, K, et al.
Published: (2003)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
by: Shipman, C, et al.
Published: (2002)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
by: De Leenheer, E, et al.
Published: (2004)

Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001)

Role of osteoprotegerin (OPG) in cancer.
by: Holen, I, et al.
Published: (2006)

The role of osteoprotegerin in breast and prostate cancer
by: Holen, I, et al.
Published: (2002)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
by: Clive Henry Buckle, et al.
Published: (2012-01-01)

Bisphosphonates--mechanisms of action in multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
by: Locklin, R, et al.
Published: (2007)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
by: Holen, I, et al.
Published: (2002)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Anti-tumour activity of bisphosphonates in human myeloma cells.
by: Shipman, C, et al.
Published: (1998)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
by: Eaton, C, et al.
Published: (2004)

Tumor-host cell interactions in the bone disease of myeloma.
by: Fowler, J, et al.
Published: (2011)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
by: Croucher, P, et al.
Published: (2002)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
by: Shipman, C, et al.
Published: (2002)

Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma.
by: Martin Trepel, et al.
Published: (2012-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
by: Locklin, R, et al.
Published: (2005)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
by: Shipman, C, et al.
Published: (1997)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
by: Holen, I, et al.
Published: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
by: Eaton, C, et al.
Published: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
by: Croucher, P, et al.
Published: (2002)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
by: Shipman, C, et al.
Published: (1998)

Incidence of Extramedullary Myeloma in Multiple Myeloma Patients
by: Sinan Demircioğlu, et al.
Published: (2019-07-01)

Investigation of Gene Expressions of Myeloma Cells in the Bone Marrow of Multiple Myeloma Patients by Transcriptome Analysis
by: Melda Sarıman, et al.
Published: (2019-01-01)

Myeloma cells decrease EphB4 expression in osteoblasts: A novel mechanism for regulation of bone formation in multiple myeloma
by: Bates, A, et al.
Published: (2007)

Myeloma cells decrease EphB4 expression in osteoblasts; A novel mechanism for regulation of bone formation in multiple myeloma
by: Bates, A, et al.
Published: (2007)

Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells
by: Maria Teresa Palano, et al.
Published: (2020-09-01)

The Bone Marrow Microenvironment in Multiple Myeloma
by: Edwards, C
Published: (2010)

Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro
by: Roelofs, A, et al.
Published: (2005)

Expression of PRAME gene in multiple myeloma
by: I В Abramenko, et al.
Published: (2004-07-01)